510 related articles for article (PubMed ID: 27476742)
21. Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL.
Gianotti N; Galli L; Racca S; Salpietro S; Cossarini F; Spagnuolo V; Barda B; Canducci F; Clementi M; Lazzarin A; Castagna A
J Antimicrob Chemother; 2012 Jan; 67(1):213-7. PubMed ID: 21987242
[TBL] [Abstract][Full Text] [Related]
22. Investigating rates and predictors of viral blips, low-level viraemia and virological failure in the Australian HIV observational database.
Han WM; Broom J; Bopage R; Templeton DJ; Edmiston N; Petoumenos K;
Trop Med Int Health; 2024 Jan; 29(1):42-56. PubMed ID: 38009461
[TBL] [Abstract][Full Text] [Related]
23. Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy.
Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Huang SH; Huang YC; Su YC; Liu WC; Hung CC
Int J Infect Dis; 2021 Apr; 105():147-151. PubMed ID: 33592339
[TBL] [Abstract][Full Text] [Related]
24. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort.
Álvarez H; Rava M; Martínez C; Portilla J; Peraire J; Rivero A; Cervero M; Mariño A; Poveda E; Llibre JM;
HIV Med; 2022 Sep; 23(8):825-836. PubMed ID: 35234328
[TBL] [Abstract][Full Text] [Related]
25. Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study.
Leierer G; Grabmeier-Pfistershammer K; Steuer A; Geit M; Sarcletti M; Haas B; Kanatschnig M; Rappold M; Zangerle R; Ledergerber B; Taylor N;
PLoS One; 2015; 10(11):e0142923. PubMed ID: 26566025
[TBL] [Abstract][Full Text] [Related]
26. Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study.
Hermans LE; Carmona S; Nijhuis M; Tempelman HA; Richman DD; Moorhouse M; Grobbee DE; Venter WDF; Wensing AMJ
PLoS Med; 2020 Feb; 17(2):e1003037. PubMed ID: 32097428
[TBL] [Abstract][Full Text] [Related]
27. Low-Level Viremia among Adults Living with HIV on Dolutegravir-Based First-Line Antiretroviral Therapy Is a Predictor of Virological Failure in Botswana.
Bareng OT; Moyo S; Mudanga M; Sebina K; Koofhethile CK; Choga WT; Moraka NO; Maruapula D; Gobe I; Motswaledi MS; Musonda R; Nkomo B; Ramaabya D; Chebani T; Makuruetsa P; Makhema J; Shapiro R; Lockman S; Gaseitsiwe S
Viruses; 2024 May; 16(5):. PubMed ID: 38793602
[TBL] [Abstract][Full Text] [Related]
28. Outcomes following detection of low level plasma HIV RNA in HIV-infected patients previously virologically suppressed on antiretroviral therapy: a retrospective observational study.
Warren AM; Cheng AC; Watson K; Lewin SR; Hoy JF
Sex Health; 2017 Jun; 14(3):238-243. PubMed ID: 28445685
[TBL] [Abstract][Full Text] [Related]
29. Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial).
Soulié C; Assoumou L; Darty M; Rodriguez C; Donati F; Sayon S; Peytavin G; Valantin MA; Caby F; Schneider L; Canestri A; Costagliola D; Katlama C; Calvez V; Marcelin AG;
J Antimicrob Chemother; 2015 Dec; 70(12):3339-44. PubMed ID: 26396157
[TBL] [Abstract][Full Text] [Related]
30. Virological Suppression and Patterns of Resistance Amongst Patients on Antiretroviral Therapy at 4 Nigerian Military Hospitals.
Babajide K; Ayemoba O; Terfa K; Ake J; Crowell TA; Adamu Y; Mohammed T; Okoye I; Odeyemi S; Crawford K; Hughes L; Akintunde E; Umar T; Hamm TE; Njoku OS
Curr HIV Res; 2017; 15(2):146-151. PubMed ID: 28521719
[TBL] [Abstract][Full Text] [Related]
31. Frequency of Viremic Episodes in HIV-Infected Women Initiating Antiretroviral Therapy During Pregnancy: A Cohort Study.
Myer L; Dunning L; Lesosky M; Hsiao NY; Phillips T; Petro G; Zerbe A; McIntyre JA; Abrams EJ
Clin Infect Dis; 2017 Feb; 64(4):422-427. PubMed ID: 27927852
[TBL] [Abstract][Full Text] [Related]
32. Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho.
Amstutz A; Nsakala BL; Vanobberghen F; Muhairwe J; Glass TR; Namane T; Mpholo T; Battegay M; Klimkait T; Labhardt ND
PLoS Med; 2020 Sep; 17(9):e1003325. PubMed ID: 32936795
[TBL] [Abstract][Full Text] [Related]
33. Does gender or mode of HIV acquisition affect virological response to modern antiretroviral therapy (ART)?
Saunders P; Goodman AL; Smith CJ; Marshall N; O'Connor JL; Lampe FC; Johnson MA
HIV Med; 2016 Jan; 17(1):18-27. PubMed ID: 26140659
[TBL] [Abstract][Full Text] [Related]
34. Predictive factors of viral load high-risk events for virological failure in HIV/AIDS patients receiving long-term antiviral therapy.
Qin S; Lai J; Zhang H; Wei D; Lv Q; Pan X; Huang L; Lan K; Meng Z; Liang H; Ning C
BMC Infect Dis; 2021 May; 21(1):448. PubMed ID: 34006230
[TBL] [Abstract][Full Text] [Related]
35. Determinants of virological failure and antiretroviral drug resistance in Mozambique.
Rupérez M; Pou C; Maculuve S; Cedeño S; Luis L; Rodríguez J; Letang E; Moltó J; Macete E; Clotet B; Alonso P; Menéndez C; Naniche D; Paredes R
J Antimicrob Chemother; 2015 Sep; 70(9):2639-47. PubMed ID: 26084302
[TBL] [Abstract][Full Text] [Related]
36. Low-level viraemia among people living with HIV in Nigeria: a retrospective longitudinal cohort study.
Chun HM; Abutu A; Milligan K; Ehoche A; Shiraishi RW; Odafe S; Dalhatu I; Onotu D; Okoye M; Oladipo A; Gwamna J; Ikpeazu A; Akpan NM; Ibrahim J; Aliyu G; Akanmu S; Boyd MA; Swaminathan M; Ellerbrock T; Stafford KA; Dirlikov E;
Lancet Glob Health; 2022 Dec; 10(12):e1815-e1824. PubMed ID: 36400087
[TBL] [Abstract][Full Text] [Related]
37. HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen.
Martinez V; Marcelin AG; Morini JP; Deleuze J; Krivine A; Gorin I; Yerly S; Perrin L; Peytavin G; Calvez V; Dupin N
AIDS; 2005 Jul; 19(10):1065-9. PubMed ID: 15958838
[TBL] [Abstract][Full Text] [Related]
38. Very high baseline HIV viremia impairs efficacy of non-nucleoside reverse transcriptase inhibitor-based ART: a long-term observation in treatment-naïve patients.
Chen S; Han Y; Song XJ; Li YL; Zhu T; Lu HZ; Tang XP; Zhang T; Zhao M; He Y; He SH; Wang M; Li YZ; Huang SB; Li Y; Liu J; Cao W; Li TS
Infect Dis Poverty; 2020 Jun; 9(1):75. PubMed ID: 32571409
[TBL] [Abstract][Full Text] [Related]
39. Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children.
Mulu A; Liebert UG; Maier M
BMC Infect Dis; 2014 Jan; 14():28. PubMed ID: 24422906
[TBL] [Abstract][Full Text] [Related]
40. Temporal dynamics and drivers of durable HIV viral load suppression and persistent high- and low-level viraemia during Universal Test and Treat scale-up in Uganda: a population-based study.
Rosen JG; Ssekubugu R; Chang LW; Ssempijja V; Galiwango RM; Ssekasanvu J; Ndyanabo A; Kisakye A; Nakigozi G; Rucinski KB; Patel EU; Kennedy CE; Nalugoda F; Kigozi G; Ratmann O; Nelson LJ; Mills LA; Kabatesi D; Tobian AAR; Quinn TC; Kagaayi J; Reynolds SJ; Grabowski MK
J Int AIDS Soc; 2024 Feb; 27(2):e26200. PubMed ID: 38332519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
